Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E, et al. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127:1863–9.
Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10:147–56.
Marchi E, O’Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. CA Cancer J Clin. 2020;70:47–70.
Gisselbrecht C, Gaulard P, Lepage E, Coiffier B, Brière J, Haioun C, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin’s lymphomas. Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Blood 1998;92:76–82.
Schmitz N, Lenz G, Stelljes M. Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas. Blood. 2018;132:245–53.
Muranushi H, Shindo T, Hishizawa M, Tokunaga M, Wake A, Nakano N, et al. GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma. Bone marrow Transplant. 2021;56:155–66.
Gong K, Xie J, Yi H, Li W. CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1 arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells. Biochem J. 2012;443:735–46.
Ning ZQ, Li ZB, Newman MJ, Shan S, Wang XH, Pan DS, et al. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity. Cancer Chemother Pharmacol. 2012;69:901–9.
Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, et al. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015;26:1766–71.
Shi Y, Jia B, Xu W, Li W, Liu T, Liu P, et al. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol. 2017;10:69.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.
Guo W, Cao Y, Liu J, Zheng X, Wang M, Zheng Y, et al. Chidamide maintenance therapy in high-risk T-ALL/T-LBL after allo-HSCT: a prospective, single-center, single-arm study. Bone Marrow Transplant. 2023;58:1163–6.
Funding
This work was supported by grants from the National Key Research and Development Program of China (grant no. 2022YFA1103500) and the National Natural Science Foundation of China (grant no. 82170210).
Author information
Authors and Affiliations
Contributions
YMZ and HH designed the study. WHC collected and analyzed the data and wrote the manuscript. JMS, YL, JY, XYL, LZL and HRF contributed to patient recruitment and treatment. All authors reviewed the manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval
The entire study procedure was in accordance with the Declaration of Helsinki and was approved by the Ethics Review Committee of the First Affiliated Hospital of Zhejiang University (IIT20230004C). Written informed consent was obtained from each patient or parent/legal representative.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chen, W., Shi, J., Luo, Y. et al. Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma. Bone Marrow Transplant 59, 561–563 (2024). https://doi.org/10.1038/s41409-023-02191-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-023-02191-1
- Springer Nature Limited